← the graveyard
Tafamidis Meglumine Capsule
no longer on the FDA list · Cardiovascular · Removed 2026-09-30
This drug was removed from the FDA's shortage list on 2026-09-30. The FDA does not say why a listing is removed. What follows is the last record we saw, from the 2026-09-29 snapshot, when its status was being discontinued. It is an archive, not current information, and it is not counted in any figure elsewhere on this site.
- Manufacturers listed (last seen)
- Pfizer Inc.
- Machine-readable
- JSON for this drug
Presentations as last listed (1)
| Presentation | Company | Availability | Updated |
|---|---|---|---|
| Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC 0069-8730-30) | Pfizer Inc. | unknown | 09/29/2025 |
History
Daily tracking of this drug began 2026-08-25 (the first day of the archive).
- 2026-09-30 — Tafamidis Meglumine Capsule was removed from the FDA list (was being discontinued)
Each daily snapshot is compared with the one before it; status changes, availability-wording revisions, and arrivals or removals are listed here. A change the FDA makes and reverses between two snapshots is not seen. Every daily record is kept in the public repository.
Not medical advice. ShortSupply republishes the FDA's drug-shortage data with history added. Talk to your pharmacist or prescriber about your situation — never change medication based on this site.